DNA

AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)

Significant reduction of toxic protein aggregate, Poly(GP) Significant increase in biomarker of target engagement, sGPNMB AIT-101 and active metabolites crossed...

CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation

CareDx Exclusive Provider of dd-cfDNA Testing Services for Use in Miromatrix Clinical Trials Companies at Forefront of Alternative Organ Supply...

Inovalon Expands Patient Data Connectivity Network by 110% Over 12 Months – Now Enabling Access to More Than 67% of U.S. Healthcare Providers

Expanded Access Further Eases Patient Data Exchange and Advances Industry InteroperabilityBOWIE, Md., April 04, 2023 (GLOBE NEWSWIRE) -- Inovalon, a...

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer

BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...

Aerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2

DURHAM, N.C., April 03, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life...

Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology

Results from three participants demonstrated no incidence of acute rejection at durations of 56, 154, and 232 days Strong graft...

Transplant Logistics Leader MediGO Issues Statement Welcoming HRSA Announcement on Organ Procurement and Transplantation Network Modernization Initiative

BALTIMORE, March 30, 2023 (GLOBE NEWSWIRE) -- MediGO, a Baltimore-based digital healthcare supply chain technology company focused on improving equity,...

NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth

TORONTO and TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX)...

Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the...

error: Content is protected !!